Status:
RECRUITING
Exploring the Correlation Between MRI Image Characteristics and Diagnosis, Pathology and Prognosis in Patients With Prostate Lesions
Lead Sponsor:
Zhen Li
Conditions:
Prostate Carcinoma
MRI
Eligibility:
MALE
18+ years
Brief Summary
Globally, prostate cancer is the second most common malignant tumor and the fifth leading cause of cancer-related death in men. In China, there will be more than 125,000 new cases of prostate cancer i...
Detailed Description
Globally, prostate cancer is the second most common malignant tumor and the fifth leading cause of cancer-related death in men. In China, there will be more than 125,000 new cases of prostate cancer i...
Eligibility Criteria
Inclusion
- Patients with abnormal prostate-specific antigen (PSA) elevated (\>4.0 ng/ml) or abnormal digital rectal examination (DRE) or suspicious lesions found by prostate ultrasound, CT or MRI in the hospital
- Age/Gender: Adult male
- Patients who voluntarily participate in clinical trials and sign a written informed consent form for subjects
Exclusion
- Patients with pacemakers, unknown materials, metal implants in the body, neurostimulators, and claustrophobia
- Patients who underwent biopsy, local ablation, prostate surgery, or endocrine therapy, chemotherapy, radiotherapy and other anti-tumor treatments before examination
Key Trial Info
Start Date :
February 25 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06946771
Start Date
February 25 2025
End Date
December 31 2028
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China